medical decision support medical decision support
Sign In

Classification for Grading Hearing Loss in Child Treated with Cisplatin

Purpose: To classify the hearing loss that occurs in children treated with cisplatin using the scheme of Brock et al.

Description

Brock et al developed a classification scheme for grading the high-frequency hearing loss that can occur in a child treated with cisplatin. This can help identify children who may benefit from interventions to improve hearing. The authors are from the Hospital for Sick Children in London and the Royal Marsden Hospital in Sutton Surrey, England.


 

Patient selection: child receiving chemotherapy with cisplatin (maximum age was 13.5 years)

 

Features of hearing loss associated with cisplatin therapy:

(1) The risk is greater if the dose is >= 400 mg per square meter BSA.

(2) The hearing loss tends to affect higher frequencies.

(3) A hearing threshold of >= 40 dB indicates significant hearing loss.

(4) High frequency hearing loss may make speech incomprehensible and some consonants inaudible.

Bilateral Hearing Loss >= 40 dB

Bilateral Hearing Loss < 40 dB

Grade

none

at all frequencies

0

at 8,000 Hz

at < 8,000 Hz

1

at >= 4,000 Hz

at < 4,000 Hz

2

at >= 2,000 Hz

at < 2,000 Hz

3

at >= 1,000 Hz

at < 1,000 Hz

4

 


To read more or access our algorithms and calculators, please log in or register.

Specialty

Objective

ICD-10